The dip in this biotech name is a "tactical buying opportunity" - Mizuho Securities Sep 26, 2023 08:50AM
Biotechs Trade at a "Very Attractive Discount", Set for "Outperformance in 2022" - Analyst Defends Biotechnology Sector in the Face of Weakness Jun 1, 2022 06:53AM
XBI Will Rebound, COVID Will Ease, Gene Therapy Approvals to Triple, Focus on NASH to Return - William Blair Biotech Predictions for 2022 Dec 29, 2021 08:15AM